Skip to main content

Table 1 HDACis under clinical development

From: Histone acetylation: novel target for the treatment of acute lymphoblastic leukemia

Chemical structure Name Target Study phase
Hydroxamates SAHA (vorinostat) Pan-inhibitor Phase III alone or in combination
PXD101 (belinostat) Pan-inhibitor Phase II alone or in combination
LBH589 (panobinostat) Pan-inhibitor Phase II alone or in combination
ITF2357 (givinostat) Pan-inhibitor Phase II alone or in combination
4SC-201 (resminostat) Pan-inhibitor Phase II alone or in combination
PCI 24781 (abexinostat) Classes I and II Phase II alone or in combination
Cyclic peptides Depsipeptide/FK228 (romidepsin) Classes I phase III alone or in combination
Aliphatic fatty acids Valproic acid Classes I and IIa Phase II alone or in combination
Butyrate Classes I and IIa Phase II alone or in combination
Benzamides MS-275 (entinostat) Class I Phase II alone or in combination
MGCD0103 (mocetinostat) Class I/IV Phase II alone or in combination
  1. HDACis HDAC inhibitors